Literature DB >> 2211374

Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells.

M Yoshida1, Y Hoshikawa, K Koseki, K Mori, T Beppu.   

Abstract

Biological activities of four chemically synthesized trichostatin-related compounds, (R)-trichostatin A, (S)-trichostatin A, (R)-trichostatic acid, and (S)-trichostatic acid, were investigated. Assays of differentiation-inducing activity in Friend leukemia cells and G2-arresting activity in the cell cycle of normal rat fibroblast cells were used as monitoring systems for comparing the bioactivities of these compounds. The results clearly showed that both of the enantiomers of trichostatic acid had no activity in both the assay systems. In the case of (S)-trichostatin A, the antipode of naturally occurring trichostatin A, 50% effective concentrations were determined to be 50-70-fold higher than those of (R)-trichostatin A. The relationship between this ratio and the value of enantiomeric excess strongly suggests that (S)-trichostatin A is also biologically inactive. These results indicate that the absolute configuration and the presence of the hydroxamate group of trichostatin A are essential for its biological activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211374     DOI: 10.7164/antibiotics.43.1101

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  15 in total

Review 1.  Chromatin modification and disease.

Authors:  C A Johnson
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

2.  Age-related macular degeneration (AMD) mitochondria modulate epigenetic mechanisms in retinal pigment epithelial cells.

Authors:  Sonali Nashine; Anthony B Nesburn; Baruch D Kuppermann; M Cristina Kenney
Journal:  Exp Eye Res       Date:  2019-06-19       Impact factor: 3.467

3.  Acetylation of Mammalian ADA3 Is Required for Its Functional Roles in Histone Acetylation and Cell Proliferation.

Authors:  Shakur Mohibi; Shashank Srivastava; Aditya Bele; Sameer Mirza; Hamid Band; Vimla Band
Journal:  Mol Cell Biol       Date:  2016-09-12       Impact factor: 4.272

4.  Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression.

Authors:  L M del Mar Peña; L A Laimins
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 5.  The pituitary tumour epigenome: aberrations and prospects for targeted therapy.

Authors:  Kiren Yacqub-Usman; Alan Richardson; Cuong V Duong; Richard N Clayton; William E Farrell
Journal:  Nat Rev Endocrinol       Date:  2012-04-24       Impact factor: 43.330

Review 6.  Histone-mediated epigenetics in addiction.

Authors:  Leah N Hitchcock; K Matthew Lattal
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

7.  Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.

Authors:  Yasuyuki Miyake; Jeremy J Keusch; Longlong Wang; Makoto Saito; Daniel Hess; Xiaoning Wang; Bruce J Melancon; Paul Helquist; Heinz Gut; Patrick Matthias
Journal:  Nat Chem Biol       Date:  2016-07-25       Impact factor: 15.040

8.  A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.

Authors:  Sunil Sharma; James Symanowski; Bryan Wong; Pamela Dino; Phillip Manno; Nicholas Vogelzang
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

Review 9.  Histone deacetylase inhibitors and cell death.

Authors:  Jing Zhang; Qing Zhong
Journal:  Cell Mol Life Sci       Date:  2014-06-05       Impact factor: 9.261

10.  Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

Authors:  Albert Bowers; Nathan West; Jack Taunton; Stuart L Schreiber; James E Bradner; Robert M Williams
Journal:  J Am Chem Soc       Date:  2008-07-19       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.